These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28694146)

  • 21. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.
    Scalfaro E; Streefkerk HJ; Merz M; Meier C; Lewis D
    Drug Saf; 2017 Aug; 40(8):715-727. PubMed ID: 28508325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.
    Cherkas Y; Ide J; van Stekelenborg J
    Drug Saf; 2022 May; 45(5):571-582. PubMed ID: 35579819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Causality Assessment in Pharmacovigilance: Still a Challenge.
    Ralph Edwards I
    Drug Saf; 2017 May; 40(5):365-372. PubMed ID: 28247280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tool to assess causality of direct and indirect adverse events associated with therapeutic interventions.
    Zorzela L; Mior S; Boon H; Gross A; Yager J; Carter R; Vohra S
    Curr Med Res Opin; 2018 Mar; 34(3):407-414. PubMed ID: 28933962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).
    Shimabukuro TT; Nguyen M; Martin D; DeStefano F
    Vaccine; 2015 Aug; 33(36):4398-405. PubMed ID: 26209838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study.
    Schutte T; Tichelaar J; Reumerman MO; van Eekeren R; Rolfes L; van Puijenbroek EP; Richir MC; van Agtmael MA
    Drug Saf; 2017 May; 40(5):409-418. PubMed ID: 28120270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of the revised WHO causality assessment protocol for adverse events following immunization in India.
    Singh AK; Wagner AL; Joshi J; Carlson BF; Aneja S; Boulton ML
    Vaccine; 2017 Jul; 35(33):4197-4202. PubMed ID: 28648545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison of two methods to assess causality of adverse drug reactions].
    Kyonen M; Folatre I; Lagos X; Vargas S
    Rev Med Chil; 2015 Jul; 143(7):880-6. PubMed ID: 26361025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can decisional algorithms replace global introspection in the individual causality assessment of spontaneously reported ADRs?
    Macedo AF; Marques FB; Ribeiro CF
    Drug Saf; 2006; 29(8):697-702. PubMed ID: 16872243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Child overdose: the value of the French pharmacovigilance causality assessment method.
    Rajab M; Lagier G; Eftekhari P; Ginisty S; Bazire A; Garnier R
    Therapie; 2004; 59(6):603-6. PubMed ID: 15789822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of Spontaneously Reported Adverse Events].
    Nakamura M
    Yakugaku Zasshi; 2016; 136(4):549-56. PubMed ID: 27040337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system].
    Aguirre C; García M
    Med Clin (Barc); 2016 Nov; 147(10):461-464. PubMed ID: 27450163
    [No Abstract]   [Full Text] [Related]  

  • 38. Active surveillance for adverse events following immunization.
    Crawford NW; Clothier H; Hodgson K; Selvaraj G; Easton ML; Buttery JP
    Expert Rev Vaccines; 2014 Feb; 13(2):265-76. PubMed ID: 24350637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions.
    Belhekar MN; Taur SR; Munshi RP
    Indian J Pharmacol; 2014; 46(1):117-20. PubMed ID: 24550597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MOdified NARanjo Causality Scale for ICSRs (MONARCSi): A Decision Support Tool for Safety Scientists.
    Comfort S; Dorrell D; Meireis S; Fine J
    Drug Saf; 2018 Nov; 41(11):1073-1085. PubMed ID: 29876835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.